NK3 receptor antagonists for the treatment of schizophrenia

Herbert Meltzer*, Adam Prus

*Corresponding author for this work

Research output: Contribution to journalReview article

28 Scopus citations

Abstract

The ability of NK3 receptor antagonists to enhance dopaminergic, serotonergic, noradrenergic, cholinergic and GABAergic release in the limbic system, cortex, hippocampus and striatum, all of which have been implicated in schizophrenia and the mechanism of action of antipsychotic drugs, is a principal reason for interest in this class of drugs as a possible monotherapy or augmentation treatment for schizophrenia. In addition, two NK3 receptor antagonists, osanetant and talnetant, have been studied in patients with schizophrenia, with some evidence for efficacy (osanetant).

Original languageEnglish (US)
Pages (from-to)555-560
Number of pages6
JournalDrug Discovery Today: Therapeutic Strategies
Volume3
Issue number4
DOIs
StatePublished - Jun 1 2006

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'NK<sub>3</sub> receptor antagonists for the treatment of schizophrenia'. Together they form a unique fingerprint.

  • Cite this